RayKnowChina Research Map
Shortlist

Cancer

Breast cancer in Shenyang

沈阳 乳腺癌

All diseases in Shenyang

3 hospitals in Shenyang

Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shenyang may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 130 papers led
  2. 75 papers led
  3. 63 papers led

Breast cancer in every city Shenyang on the disease page, with the national map

47

open trials on breast cancer with a hospital in Shenyang

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shenyang as lead sponsor or study site. 21 of them are led by a hospital in Shenyang. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07281976

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou

  2. Recruiting
    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
    Phase
    Not given
    Started
    2026-01
    Posted
    Registry
    NCT07347600

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou

  3. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  4. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07876557

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou

  5. Recruiting
    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT06757634

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou

  6. Recruiting
    A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
    Phase
    Phase 2/Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT06926868

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou

  7. Recruiting
    A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07003074

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan

  8. Recruiting
    Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07008976

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou

  9. Recruiting
    A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07043725

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou

  10. Recruiting
    JS207 Combination Therapy in Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07045311

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou

  11. Recruiting
    TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-07
    Posted
    Registry
    NCT07047365

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 44 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guiyang, Haikou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Luzhou, Nanchang, Nanchong, Nanjing, Nanning, Ningbo, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Tangshan, Tianjin, Weifang, Wenzhou, Xi'an, Xiangyang, Xining, Xinxiang, Xuzhou, Zhengzhou

  12. Recruiting
    A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07169994

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang

  13. Recruiting
    Optimal Application Timing of ADC Drugs for Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07657130

    Age 18 years to 75 years; women only (registered criteria)

    Led by Liaoning Cancer Hospital & InstituteShenyang

  14. Recruiting
    A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT07673029

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou

  15. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  16. Recruiting
    Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06282796

    Age 18 years to 80 years; women only (registered criteria)

    Led by First Hospital of China Medical University; 2 listed hospitals as study sitesFuzhou, Shenyang

  17. Recruiting
    SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06340230

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  18. Recruiting
    The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06690645

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  19. Recruiting
    The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer
    Phase
    Not given
    Started
    2024-11
    Posted
    Registry
    NCT06698679

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  20. Recruiting
    A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05635487

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  21. Recruiting
    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
    Phase
    Phase 3
    Started
    2023-10
    Posted
    Registry
    NCT05696626

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou

  22. Recruiting
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT05860465

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan

  23. Recruiting
    Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05891093

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  24. Recruiting
    Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
    Phase
    Phase 3
    Started
    2023-06
    Posted
    Registry
    NCT05909332

    Age 18 years to 70 years; women only (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou

  25. Recruiting
    A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
    Phase
    Phase 1/Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06064812

    Age 18 years to Not stated; women only (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  26. Recruiting
    JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06079983

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  27. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

  28. Recruiting
    BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-12
    Posted
    Registry
    NCT06120283

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang

  29. Recruiting
    Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
    Phase
    Phase 2
    Started
    2023-09
    Posted
    Registry
    NCT06165900

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  30. Recruiting
    Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC
    Phase
    Phase 2
    Started
    2022-02
    Posted
    Registry
    NCT05228951

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  31. Recruiting
    The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
    Phase
    Not given
    Started
    2022-08
    Posted
    Registry
    NCT05263570

    Age 18 years to Not stated; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  32. Recruiting
    Prone Positioning CT Scan and Ultrasound Assessing Axillary Lymph Nodes in Patients With Breast Cancer Official Title: Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer
    Phase
    N/A
    Started
    2022-03
    Posted
    Registry
    NCT05346510

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  33. Recruiting
    Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05579366

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan

  34. Recruiting
    Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05638594

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  35. Recruiting
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2022-01
    Posted
    Registry
    NCT05851014

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou

  36. Recruiting
    Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-07
    Posted
    Registry
    NCT04136782

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  37. Recruiting
    Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT
    Phase
    Phase 3
    Started
    2021-07
    Posted
    Registry
    NCT04137653

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  38. Recruiting
    Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
    Phase
    Not given
    Started
    2021-07
    Posted
    Registry
    NCT04476485

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 3 listed hospitals as study sitesChangchun, Harbin, Shenyang

  39. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

  40. Recruiting
    Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
    Phase
    Phase 2
    Started
    2021-08
    Posted
    Registry
    NCT04983121

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  41. Recruiting
    Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy
    Phase
    N/A
    Started
    2021-11
    Posted
    Registry
    NCT05241119

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang

  42. Recruiting
    Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer
    Phase
    Not given
    Started
    2019-10
    Posted
    Registry
    NCT04065321

    Age 18 years to 60 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang

  43. Not yet recruiting
    Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
    Phase
    Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07795424

    Age 18 years to 70 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical University; 1 listed hospital as study siteShenyang

  44. Not yet recruiting
    Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
    Phase
    Phase 2
    Started
    2024-02
    Posted
    Registry
    NCT06202313

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  45. Not yet recruiting
    Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
    Phase
    Phase 3
    Started
    2021-08
    Posted
    Registry
    NCT04973319

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  46. Enrolling by invitation
    A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07376629

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou

  47. Enrolling by invitation
    Real-world Study on Shenbailing Granules for Improving Qi and Blood Deficiency in Patients After Breast Cancer Surgery
    Phase
    N/A
    Started
    2024-12
    Posted
    Registry
    NCT06881550

    Age 18 years to 75 years; women only (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Shenyang

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Shenyang, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Central Hospital of Shenyang Medical College沈阳医学院附属中心医院nonenonenonenonenonenonenonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine辽宁中医药大学附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone21 opennonenonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenone
China Shenyang Chest Hospital沈阳市胸科医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Fifth People Hospital沈阳市第五人民医院nonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Hospital of China Medical University中国医科大学附属第一医院57612 open1091 open1514 open461301 open53nonenone0562140none226none1none0none669nonenonenone1751 opennone20none3none3none0none1nonenone4nonenone112nonenone10nonenonenonenonenone
Fourth Affiliated Hospital of China Medical University中国医科大学附属第四医院nonenone1120188nonenonenonenonenone2none20nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
General Hospital, China Medical University中国人民解放军北部战区总医院nonenonenonenonenonenonenonenonenonenonenone2none2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Liaoning Cancer Hospital & Institute辽宁省肿瘤医院none916402 open602 open6751 open21nonenonenone112nonenonenonenonenonenone5nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Northern Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
People's Hospital, China Medical University辽宁省人民医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine辽宁中医药大学附属第二医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Shengjing Hospital of China Medical University中国医科大学附属盛京医院5none601 open27991 open522 open6319 open471 open02none2561017nonenonenone11none000none234none2421232none1none5none20none011none4nonenone10100nonenonenonenonenonenonenone
Shenyang Northern Hospitalnonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone04 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Shenyang.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for breast cancer.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shenyang on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data